Skip to main content
. 2015 Dec 21;10(12):e0144824. doi: 10.1371/journal.pone.0144824

Fig 7. Effect of β-Blockers and AT2R agonists on cell viability and effect of novel AT2R agonist NP-6A4 on MCL-1 expression in Human Coronary Artery Vascular Smooth Muscles Cells.

Fig 7

(A) Graph shows data from Cell the cell viability assessment using MTS proliferation assay kit. Treatment with β-Blockers did not significantly alter cell viability of hCAVSMCs while treatment with NP-6A4 resulted in the highest increase in the number of the viable cells. Data presented as means ± SEM, n≥3 and *p<0.05 compared to control (B) Representative images of immunofluorescence staining with anti-MCL-1 antibody and nuclear stain DAPI in hCAVSMCs in response to treatment by NP-6A4 (scale bars = 50 μm). (C) Quantification of MCL-1 expression in hCAVSMCs. Data is shown as means ± SEM, n≈20 and *p<0.05 compared to control as determined by Student’s 2-tailed T-test. Thus, NP-6A4 mediated increase in MCL-1 expression is a common signaling mechanism in mouse HL-1 cardiomyocytes and hCAVSMCs.